NCT00343460 2026-03-02
APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
Heron Therapeutics
Phase 3 Completed
Clinical Trials
9 trialsNCT03204279 2024-06-25
CINV
Helsinn Healthcare SA
Phase 2 Completed
NCT03649230 2023-08-18
EVOLVE_CINV
Purdue Pharma, Canada
Completed
NCT01363479 2021-09-22
An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT03403712 2020-06-01
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Helsinn Healthcare SA
Phase 3 Completed
NCT01636947 2018-09-25
KMEC
Merck Sharp & Dohme LLC
Phase 4 Completed
NCT02557035 2018-06-20
An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed
NCT00601172 2018-01-17
A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.
GlaxoSmithKline
Phase 3 Completed
NCT01339260 2014-11-26
An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting
Helsinn Healthcare SA
Phase 3 Completed